Webinar

The Nasal Drug Delivery Journey: from Systemic to Nose-to-Brain?

Read description

By 2030, there will be 1 billion people over 65 years of age worldwide compared to 600 million currently, and healthcare must adjust to this changing demography. In addition, we are faced with multiple unmet medical needs and healthcare costs are rising globally. As a consequence several adaptations are necessary, including new therapeutic options, shortened in-patient hospital stays, increased outpatient care and more self-administration of drugs.

The Central Nervous System (CNS) drug market is of interest as it comprises several areas, some with high unmet medical needs, such as depression, schizophrenia, Alzheimer's disease, Parkinson's disease, migraine, insomnia, ADHD (Attention Deficiency Hyperactivity Disorder), anxiety disorders and bipolar disorder. In 2015, the drug market for CNS was valued at $143 billion. 

Nasal drug delivery devices can play a role in meeting some of these unmet medical needs, and an area within drug delivery generating much attention is the possibility of treating CNS diseases by the so-called "nose-to-brain" route.

Speakers will cover several subjects related to the CNS market from different perspectives. A detailed review of the advantages of nasal drug delivery in relation to the unmet needs in the CNS market will be presented. The options available and the comparative technical merits of nasal devices will be discussed and Aptar Pharma will share their know-how gained from more than 30 years of experience in this specialized drug delivery field. Finally the speakers will look into the future and explore how some of these CNS diseases could possibly be treated via the nose-to-brain pathway.

Anyone interested in the growing area of CNS therapy who is considering using nasal drug delivery to find solutions for patients will benefit strongly from participating in this webinar.

Presented by

Pierre Carlotti VP Marketing Communication
Pierre is a member of Aptar Pharma’s Management Committee. He’s responsible for all aspects of marketing and communication, from marketing plans and innovation roadmaps to new business branding, technical and scientific partnerships, and, more recently, connected health programs, for the Prescription Division and, since 2013, the Injectables Division. Pierre has a postgraduate degree in Biology and is an ISCE-Paris Business School graduate. Prior to joining Aptar, Pierre worked at Sanofi and West Pharmaceutical Services.
Dr. Julie Suman President, Next Breath, LLC
Julie is co-founder and President of Next Breath, LLC, a specialty company of Aptar Pharma. She holds a B.S. in Pharmacy from Duquesne University and a Ph.D. in Pharmaceutical Sciences from the University of Maryland. She is an adjunct assistant professor at the University of Maryland and an Affiliate Assistant Professor at Virginia Commonwealth University. Her doctoral research, focusing on the relationship between in vitro tests for nasal sprays and in vivo deposition, has been recognized for excellence by an ISAM research award.
Dr. Gerallt Williams Director Scientific Affairs
After obtaining his Ph.D. from the University of Wales, UK in 1985, Gerallt has held various industrial positions at Monsanto Inc. (UK), Fisons Ltd (UK), Valois (France) and Inhale/Nektar Therapeutics (USA). Gerallt is now in charge of scientific affairs for the Aptar Pharma Prescription division, Le Vaudreuil, France and is engaged in the development of new devices for nasal, inhaled and injectable drug products.
Please register to view the webinar :Already registered ?
Mandatory fields

*The information marked with (*) is essential to process your request. Failure to provide such information may prevent us from fulfilling your request. Your personal data will be used only for Aptar to process an information request and/or job application and will be made accessible to Aptar and to any third party for exclusively technical and logistical reasons, notably to our services located outside the European Union, being specified that, in the event that the recipient country does not ensure a level of data protection equivalent to that of the European Union, Aptar undertakes to take all relevant guarantees, either on the basis of an adequacy decision or, in the absence of such a decision, on the basis of appropriate safeguards, a copy of which may be requested from the contact email below. Your personal data will only be kept for a period that does not exceed the applicable statutory limitation periods. Any contact data will be made accessible to Aptar and to third parties that provide technical and logistical support to Aptar for the purpose of your contact request.

If any after communication upon receipt of a valid identity document, you have the right to access, modify, rectify, limit, delete and ask, if any, the portability of your personal data as well as a right of opposition, if necessary subject to legitimate and imperative reasons, to the processing of such data. You may also define guidelines for the use of your personal data in the event of death.

If you wish to exercise this option or if you have any questions regarding our General Terms and Conditions of Use, Privacy and Cookies Policy, please contact Aptar at: informationgovernance@aptar.com

You also have the right to lodge a complaint at the relevant data protection authority in your own jurisdiction.

September 08, 2016 3PM London / 10AM New York 60 min
Watch now
Presented by
Pierre Carlotti VP Marketing Communication
Dr. Julie Suman President, Next Breath, LLC
Dr. Gerallt Williams Director Scientific Affairs
Read more
Key Learning Objectives
  • Learn about unmet medical needs and market opportunities for nasal drug delivery to treat CNS diseases
  • Increased understanding of nasal drug delivery devices that target CNS related diseases
  • A look at where the future might be heading with new opportunities in areas such as nose-to-brain drug delivery
  • Do you have questions about this webinar ?
Do you have questions about this webinar ?
Contact us